2020

30 Jun 2020
Golden Meditech Announces FY2019/2020 Annual Results
Hong Kong, 30 June 2020 - Golden Meditech Holdings Limited (SEHK stock code: 00801) ("Golden Meditech" or the "Company", together with its subsidiaries, the "Group"), a leading integrated healthcare enterprise in China, announces today its annual results for the year ended 31 March 2020 (the "Year").
18 Mar 2020
Golden Meditech's Associate, Cellenkos Focuses on the Development of Cell-Theray for Treatment of COVID-19 Mediated Acute Respiratory Distress Syndrome (CoV-ARDS)
Hong Kong, 18 March 2020 - Golden Meditech Holdings Limited (SEHK stock code: 00801) ("Golden Meditech"), a leading integrated healthcare enterprise in China, announced that its associate, Cellenkos, Inc. ("Cellenkos") has submitted a clinical development proposal to the Biomedical Advanced Research and Development Authority ("BARDA") to start a Phase 1/2 clinical trial with CK0802 for treatment of COVID-19 mediated acute respiratory distress syndrome ("CoV-ARDS"). Cellenkos will leverage its clinical experience with CK0802 for other inflammatory disorders, including amyotrophic lateral sclerosisand and fast-track development of CK0802 to treat respiratory complications caused by COVID-19 infection.

Please download the latest "Acrobat Reader" to view the PDF.

Back to top